Pfizer and BioNTech Win Legal Battle Over CureVac Patents in London High Court
In a major victory for Pfizer and BioNTech, the London High Court has invalidated two of CureVac's patents related to messenger RNA (mRNA) technology. This technology is crucial for the development of Pfizer and BioNTech's COVID-19 vaccine.
The legal battle between Pfizer, BioNTech, and CureVac is part of a global dispute that also includes litigation in the United States and Germany. Additionally, Pfizer and BioNTech are currently embroiled in a separate case with Moderna over their rival COVID-19 vaccines.
In a previous ruling in July, the High Court found that one of Moderna's mRNA patents was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it. However, Pfizer and BioNTech have been granted permission to appeal this decision.
Overall, this legal battle has significant implications for the pharmaceutical industry and the future of COVID-19 vaccine development. Investors should closely monitor the outcome of these cases, as they could impact the market dynamics and the companies' financial performance. Stay tuned for further updates on this ongoing legal saga.